QURE
uniQureCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
QURE vs peer average
61/100
QURE vs. peer average (C vs. D)
Grade spread
A 1 · B 1 · C 1 · D 4 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
RGNX is the first available peer comparator.
An AAV gene-therapy regulatory and platform comparator, not a same-indication valuation peer. Its program mix and funding position differ materially. Company context: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-highlights-key-2026-catalysts-and-announces-positive/
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
QURE
uniQure
RGNX
REGENXBIO
Grade
C
D
Momentum
7
19
Value
41
41
Sentiment
87
57
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs RGNX
QURE / RGNX
Grade Position
In line
QURE vs. peer average (C vs. D)
61/100
Momentum
7
RGNXValue
41
QURESentiment
87
QURERotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs QURE
RGNX is the first peer returned for this comparison set.